Q2 FY27 — 6 Nov 2026
Cohance Lifesciences Limited Q2 FY27
Cohance Lifesciences delivered sequential operating recovery in Q2 FY27, with revenue growing 13% QoQ to INR 4,767 million and adjusted EBITDA margins expanding to 10%. Growth was supported by a 34.5% sequential rebound in Pharma CDMO and steady 5% YoY growth in API+, though Specialty Chemicals faced headwinds from generic AgChem destocking. Management reiterated expectations of YoY growth in revenue and EBITDA for H2 FY27, backed by new commercial wins and order reloads, while actively addressing regulatory and CAPA matters including USFDA inspection responses and the Suryapet closure notice.
Read the full call






